Freestone Grove Partners LP Takes $8.39 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Freestone Grove Partners LP bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, Holdings Channel.com reports. The institutional investor bought 101,332 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,388,000.

Other institutional investors have also added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at approximately $28,000. Hantz Financial Services Inc. increased its holdings in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth approximately $48,000. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Down 0.9%

NASDAQ ANIP opened at $72.83 on Friday. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of 15.70 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The business’s fifty day moving average is $79.68 and its 200-day moving average is $78.65.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president owned 74,424 shares in the company, valued at $5,617,523.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 24,387 shares of company stock valued at $1,947,625. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ANIP. Guggenheim reduced their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group dropped their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.